Drug		МОА	Primary uses + Pharmacokinetics	Pharmacodynamics	Advantages   Adverse effects
	Barbiturates	Enhance GABAA receptor & inhibit glutamate and nicotinic Ach receptors	<ul> <li>For Induction of anesthesia</li> <li>Rapid onset (30-45s)</li> <li>Short duration (5 – 8 min) initial dose; redistributed</li> <li>Hepatic metabolism</li> <li>Multiple doses or prolonged infusions → prolonged sedation or unconsciousness</li> </ul>	CNS: ↓ CMRO2 → ↓ in ICP & CBFCardiovascular System: -Depress myocardial contractility → ↓ in BP and COP - Intact Baroreceptor reflexes.Respiratory system: - ↓ RR & TV. - Apnea may last for 30 to 90s - Laryngeal reflexes remain more intact compared to propofol → cough & laryngospasm.	<ul> <li>Potent anticonvulsant properties.</li> <li>Dose dependent histamine release (allergies).</li> <li>Myoclonus and hiccups.</li> <li>Absolutely contraindicated in Porphyria</li> <li>Venous irritation and tissue damage</li> <li>Thiopental can cause severe pain and tissue necrosis if injected subcutaneously or intra-arterially.</li> <li>If intra-arterial administration occurs, heparin, vasodilators, and regional sympathetic blockade may be helpful in treatment.</li> <li>Hangover effect</li> <li>Not for one day surgery</li> </ul>
IV Anesthetics	propofol	- Enhance GABAA receptor - The safest & the most widely used	<ul> <li>Induction, sedative + hypnotic &amp; Maintenance (TIVA)</li> <li>Rapid onset (30 to 45 s)</li> <li>Rapid termination of effect by redistribution, so emergence is rapid.</li> <li>Weak analgesic effects.</li> <li>Hepatic and extrahepatic metabolism</li> <li>Inactive metabolites → excreted by renal route</li> </ul>	<ul> <li>CNS:</li> <li>↓ ICP &amp; ↓ CPP due to markedly ↓ MAP.</li> <li>Anticonvulsant.</li> <li>Less PONV occurs.</li> <li>Cardiovascular System:</li> <li>↓ in preload, afterload, and contractility lead to ↓ in BP &amp; COP.</li> <li>HR is minimally affected, and baroreceptor reflex is blunted.</li> <li>Respiratory system:</li> <li>↓ RR and TV</li> <li>↓ Ventilatory response to hypoxia and hypercarbia.</li> </ul>	<ul> <li>Laryngeal &amp; pharyngeal muscle relaxation, allowing LMA insertion.</li> <li>Safe in Malignant hyperthermia (MH) &amp; Porphyria patients.</li> <li>Antiemetic properties.</li> <li>Suitable for day case surgery to avoid prolong postoperative hangover (drowsiness, ataxia).</li> <li>Situations where volatile anesthetics cannot be used (MH, transfer of sedated patients, airway surgery).</li> <li>Total IV anesthesia (TIVA)</li> <li>Venous irritation - Bacterial growth (b.c it contains soybeans)</li> <li>Lipid disorders - Myoclonus and hiccups</li> <li>Propofol infusion syndrome: Rhabdomyolysis, metabolic acidosis, cardiac failure, and renal failure</li> <li>Titrate the dose in hypovolemic, elderly, or hemodynamically compromised patients, or if administered with other anesthetic → to prevent hypotension</li> </ul>
	Etomidate	Enhance GABAA receptors	<ul> <li>Induction in CVD pts.</li> <li>It has nothing to do with analgesia</li> <li>Very high clearance in the liver and by circulating esterases to inactive metabolites</li> <li>Redistribution</li> </ul>	<ul> <li>CNS:</li> <li>No analgesic properties.</li> <li>↓ CBF, cerebral metabolic rate (CMR), and ICP</li> <li>Cardiovascular System:</li> <li>Minimal changes in HR, BP, and COP.</li> <li>Respiratory system:</li> <li>↓ RR &amp; TV</li> <li>Transient apnea may occur.</li> </ul>	<ul> <li>Short acting and potent, with CVS and RS stability, suitable for elderly and shocked patients.</li> <li>Excitatory phenomena (Involuntary limb twitches), myoclonus, so you have to give it with propofol or fentynel in small dose to reduce twitches.</li> <li>N/V</li> <li>Venous irritation and superficial thrombophlebitis</li> <li>Adrenal suppression, (Inhibits 11β &amp; 17 α hydroxylase).</li> <li>A single dose suppresses adrenal steroid synthesis for up to 24 hours.</li> <li>Repeated doses /infusion → increased mortality in ICU patients.</li> <li>Respiratory depression even in small dose</li> </ul>

	Ketamine	<ul> <li>non-competitive antagonism of NMDA receptors</li> <li>Dissociative anesthesia</li> </ul>	<ul> <li>For Induction, sedation &amp; analgesia</li> <li>(IV + IM)</li> <li>Unconsciousness in 30 to 60 s after an IV.</li> <li>Terminated by redistribution in 15 to 20 minutes.</li> <li>Elimination half-life is 2 to 3h.</li> <li>Metabolized by liver to multiple matabolites (portestaming)</li> </ul>	<ul> <li>CNS: ↑ (CBF), ↑ (CMR), and ↑ (ICP)</li> <li>- Amnesia &amp; profound analgesia.</li> <li>Cardiovascular System:</li> <li>- ↑ HR, COP, and BP</li> <li>- Used in hemodynamically compromised pts.</li> <li>Respiratory system:</li> <li>- Mild ↓ in RR &amp; TV</li> <li>- Potent bronchodilator.</li> </ul>	<ul> <li>- CVS stability makes it suitable for shocked patients.</li> <li>- Preservation of airway reflexes &amp; less respiratory depression makes it suitable for procedures – radiological interventions, radiotherapy, burns &amp; dressing changes.</li> <li>- ↑ salivation, PONV.</li> <li>- Emotional disturbance, agitation &amp; hallicunations. so we give it with propofol to decrease the chances of getting hallicunations</li> <li>- Contraindicated in patients with head trauma.</li> <li>- Not in LMA insertion, cause the laryngeal reflexes are intact</li> </ul>
Opioids		- Binding with opioid receptors (μ: mu, κ: kappa, δ: delta) - Morphine < 100x Fentanyl < 10x Sufentanil citrate < Remifentanil	<ul> <li>metabolites (norketamine).</li> <li>They mimic endogenous compounds: Endorphins, enkephalins &amp; dynorphins.</li> <li>Provides analgesia and some degree of sedation.</li> <li>Large doses → GA.</li> <li>Naloxone (antidote):</li> <li>A specific opiate receptor antagonist duration of action: 20</li> </ul>	<ul> <li>Laryngeal reflexes are maintained.</li> <li>Fentanyl: <ul> <li>Induction and maintenance of GA and to supplement regional and spinal anesthesia.</li> <li>Maintain cardiac stability.</li> </ul> </li> <li>Sufentanil citrate: Rapid elimination + <ul> <li>Relatively more rapid recovery</li> </ul> </li> <li>Alfentanil: Shorter duration of action <ul> <li>Remifentanil: Ultra short acting + rapidly</li> </ul></li></ul>	<ul> <li>Minimal cardiac effects</li> <li>No myocardial depression.</li> <li>(Mnemonics: MORPHINES):</li> <li>Miosis.</li> <li>Orthostatic hypotension.</li> <li>Respiratory depression &amp; chest wall rigidity</li> <li>Pain supression.</li> <li>Histamine release: Some peripheral vasodilation and hypotension,</li> </ul>
		Increasing the	antagonist, duration of action: 30 to 45 min. Dose may need to be repeated or as an infusion. - Reversal of analgesia, N/V, Increased sympathetic nervous system activity. - Used as premedication or as	cleared + extrahepatic metabolism by blood and tissue nonspecific esterases <b>Morphine:</b> - Hypotension + bronchoconstriction → histamine-releasing action. - Poor choice for a pt with renal failure. <b>CNS:</b>	<ul> <li>itching <ul> <li>N/V, slow gastric emptying slow, constipation</li> <li>Euphoria.</li> <li>Sedation or drowsiness.</li> <li>Bradycardia in large doses</li> <li>Urinary retention &amp; biliary colic</li> </ul> </li> <li>Drug interactions with anticonvulsant (valproate)</li> </ul>
Benzodiazepines		affinity of GABAA receptors for GABA.	<ul> <li>- Osed as preinedication of as adjunct to general anesthesia.</li> <li>- Redistribution.</li> <li>- All are metabolized in the liver.</li> <li>- Hydroxymidazolam → sedation in Pt with renal failure.</li> <li>- Diazepam clearance → ↓ elderly.</li> <li>Midazolam: water soluble, so drug of choice for IV administration</li> <li>- More rapid onset and elimination</li> <li>- The most potent amnestic</li> <li>Diazepam: Water-insoluble, so IV use can cause local irritation/pain</li> <li>Lorazepam: Water-insoluble.</li> </ul>	<ul> <li>Amnestic, anticonvulsant, anxiolytic, and sedative-hypnotic (dose-dependent manner).</li> <li>No analgesia.</li> <li>Cardiovascular System: <ul> <li>Mild systemic vasodilation and ↓ in cardiac output.</li> <li>HR is usually unchanged.</li> </ul> </li> <li>Respiratory system: <ul> <li>Mild ↓ in RR and TV.</li> <li>Respiratory depression may be more if administered with an opioid (synergism)</li> </ul> </li> </ul>	<ul> <li>Drug interactions with anticonvulsant (valproate)</li> <li>Pregnancy and labor: Risk of cleft lip and palate in the 1st trimester, CNS depression in the neonate.</li> <li>Superficial thrombophlebitis + injection pain → diazepam + lorazepam.</li> <li>Mild respiratory depression but can be marked in elderly leading to apnoea.</li> <li>Flumazenil (antidote):</li> <li>A competitive antagonist at the benzodiazepine binding site of GABAA receptors in the CNS.</li> <li>Reversal of sedative effects occurs within 2 min; peak effects at 10 min.</li> <li>Half-life is shorter than the benzodiazepine</li> <li>Metabolized to inactive metabolites in the liver.</li> <li>Contraindicated in patients receiving benzodiazepines for the control of seizures or elevated ICP.</li> </ul>

Various ion	- Present as liquids at room	CNS:	Sevoflurane (more potent):
channels in the	temperature and pressure.	- Unconsciousness and amnesia.	- Low solubility in blood→ rapid induction and emergence
CNS involved in	- Vaporized into gases for	<ul> <li>- ↑ cerebral blood flow (CBF).</li> </ul>	- Pleasant smelling (suitable for children)
	administration		- Has good bronchodilating properties
synaptic transmission	- Halothane, isoflurane,	Cardiovascular System:	- Agent of choice in asthma, bronchitis, and COPD.
(including GABAA,	sevoflurane, and desflurane are	- Myocardial depression & systemic vasodilation.	- It has little effect on the heart rate $\rightarrow$ good for CVS problems
	0.75%, 1.15%, 1.85%, and 6.0% at		- Mild respiratory and cardiac suppression
glycine, and glutamate	one atmosphere	- HR tends to be unchanged, except desflurane	- Carbon dioxide absorbents in anesthesia machines degrade sevoflurane
receptors)	- The higher the vapor pressure,		to Compound A
receptorsj	the more volatile the anesthetic.	- Sensitize the myocardium to the	
	- Blood solubility determines the	arrhythmogenic effects of catecholamines.	Desflurane:
	2	Respiratory system:	- Rapid onset and recovery of anesthesia (outpatient procedures)
	speed of build-up / elimination from blood / brain	- Respiratory depression	- One of least metabolized to toxic byproducts
	- Metabolism: hepatic	- Airway irritation and, during light levels	- Requires a special vaporizer
	- Exhalation $\rightarrow$ predominant route	of anesthesia, may precipitate coughing,	- Pungent & irritating to the airway (leading to more coughing,
	of elimination	laryngospasm, or bronchospasm	laryngospasm)
		(sevoflurane makes it more suitable)	- High inspired gas concentrations lead to a significant $\uparrow$ in BP & HR
	- <u>Nitrous Oxide</u> : MAC is 104% at	- Bronchodilator (except desflurane).	Isoflurane:
	one atmosphere	- Inhibit hypoxic pulmonary	- It causes peripheral vasodilation (drop BP) and increased CBF.
		vasoconstriction	- Moderate solubility, so recovery from anesthesia may be delayed
		Neuromuscular system:	- Isoflurane can make the heart "more sensitive" to circulating
		$-\downarrow$ in skeletal muscle tone.	catecholamines (like epinephrine).
		- May precipitate malignant hyperthermia	Halothane (not used anymore):
		<b>Renal system:</b> $\downarrow$ renal blood flow.	- Used for induction in children (sweet pleasant odor);
		<b>Hepatic System:</b> $\downarrow$ hepatic perfusion.	- Very soluble in blood and adipose tissue $ ightarrow$ Prolonged emergence
		Nitrous Oxide:	- Blood pressure usually falls.
		CNS:	- Sensitize the myocardium to the arrhythmogenic effects of
		- Antagonism of NMDA receptors in CNS.	catecholamines.
		- Weak anesthetic produce analgesia.	- Halothane hepatitis (rare).
		- Usually combined with other anesthetics.	Nitrous Oxide:
		- Used alone e.g. dental procedures.	- N/V
		Cardiovascular System:	- Risk of bone marrow depression
		- Mild myocardial depressant	- Inhibits vitamin B-12 metabolism
		- Mild sympathetic stimulant, HR and BP	- Expansion of closed gas spaces. $N_2O$ is 35x more soluble in blood than N.
		are usually unchanged.	- Contraindicated in (e.g. air embolus, pneumothorax, Middle Ear Surgery)
		- $\uparrow$ pulmonary vascular resistance.	- Diffuse into the cuff of ETT.
		Respiratory system: Little effect	- Diffusion hypoxia $\rightarrow$ low partial pressure of oxygen in the alveoli.

Inhalational Anesthetics

s (NMBD)	Depolarizing (Succinycholine: Suxamethonium)	Structurally similar to acetylcholine, activate the acetylcholine receptors (Ach), depolarization of post junctional membrane.	<ul> <li>Perform tracheal intubation.</li> <li>Facilitate ventilation.</li> <li>Provides optimal surgical operating conditions</li> </ul>	<ul> <li>Very short duration of action (onset 60 seconds/ duration 10 minutes)</li> <li>For short time intubation (Rapid sequence induction)</li> <li>Metabolized very quickly by plasma cholinesterase.</li> <li>Characterized by transient muscle fasciculations followed by relaxation.</li> <li>Acetylcholine esterase (AChE) inhibitors potentiate rather than reverse the block.</li> <li>Cardiac dysrhythmias: sinus bradycardia, junctional rhythm, and even asystole after the first dose in children and following repeated dose within a short time interval in adults.</li> <li>Hyperkalemia.( burns, RF, muscular dystrophies &amp; paraplegia.</li> <li>A transient increase in intraocular pressure - Increase in intracranial &amp; intragastic pressure.</li> <li>Myalgia: abdomen, back, and neck Histamine release.</li> <li>Succinylcholine apnea (side effect):</li> <li>Low levels of plasma cholinesterase (severe liver or kidney disease, starvation, malignancy or cardiac failure) result in prolongation of the effect</li> <li>Drug-induced inhibition of its activity, a genetically atypical enzyme Management is supportive (avoid awareness).</li> <li>Anaphylaxis. over 50% of anaphylactic reactions to NMBDs Malignant hyperthermia (MH).</li> </ul>		
Neuromuscular blocking drugs (NMBD)	Nondepolarizing blockers (2 types)	They act by competitively blocking the binding of ACh to its receptors and inhibit muscular contraction. (Slower onset than suxamethonium)	<ul> <li>Absence of fasciculations.</li> <li>Potentiation by other nondepolarizing NMBDs and volatile anesthetic agents.</li> <li>Reversal by AChE inhibitors.</li> <li>Neostigmine: <ul> <li>They inhibit the action of the AChE enzyme at the NMJ by increasing the concentration of Ach at NMJ.</li> <li>Clinical tests of adequate resolution of neuromuscular block include the ability to lift the head from the bed for 5 seconds.</li> <li>To minimize adverse effects, an antimuscarinic such as glycopyrronium or atropine must be administered along with the anticholinesterase.</li> </ul> </li> <li>Peripheral nerve stimulator: <ul> <li>Check the depth of neuromuscular blockade</li> <li>Determine that neuromuscular blockade is reversed</li> <li>At least 3 twitches on a train of four should be detected before attempting reversal</li> </ul> </li> </ul>	<ul> <li>1ST type: Benzylisoquinoliniums: A/ MIVACURIUM</li> <li>Short-acting, rapidly hydrolyzed/metabolized by plasma cholinesterase.</li> <li>Histamine release causing a transient hypotension and tachycardia.</li> <li>B/ ATRACURIUM</li> <li>Widely used and have an intermediate onset and duration of action.</li> <li>No direct cardiovascular effects.</li> <li>Metabolism is by Hofmann degradation and ester hydrolysis in the plasma &gt; causing Histamine release. Its duration of action is independent of renal and hepatic function.</li> <li>A breakdown product of atracurium, (laudanosine ) may accumulate and cause seizures</li> <li>C/ CISATRACURIUM</li> <li>Isomer of atracurium</li> <li>Hofmann degradation and does not accumulate in renal failure. Relatively slow onset of action.</li> <li>Does not release histamine, Less laudanosine.</li> <li>2ND Type is Aminosteroids: ROCURONIUM</li> <li>The most rapid onset of the clinically available non-depolarizing NMBDs.</li> <li>Intubating conditions can be achieved in 60-90 seconds after an induction dose, Increasing the dose shortens the time can be used for rapid sequence induction when Suxamethonium is contraindicated.</li> <li>An intermediate duration of action. Histamine is not released Or minimal release. Cardiovascularly is stable</li> <li>Higher incidence of anaphylactic reaction.</li> <li>Decrease the risk of hyperkalemia in patients with burns.</li> </ul>		

	- LAs are drugs	2 types:	Applications of local anesthesia:	LIDOCAINE:
	which reversibly	- Esters.	- Nerve block: (e.g., dental and other	- The most commonly used amide type local anesthetic.
	prevent the	- Amides (2i):	minor surgical procedures)	- Rapid onset and a duration of 60-75 minutes, extended with epinephrine
	transmission of	- <u>Lidocaine</u>	- Topical application: To skin for	for up to 2 hours.
	pain stimuli	- <u>Bupivacaine</u>	analgesia (e.g., benzocaine) or mucous	- Metabolized in the liver and excreted by the kidneys.
	locally at their site	- Mepivacaine , Prilocaine ,	membranes (for diagnostic procedures)	- Contraindicated in patients with a known sensitivity.
	of administration.	<u>Ropivacaine</u>	- Spinal & epidural anesthesia:	- Has also antiarrhythmic action.
	- Reversibly	- Potency of local anesthetics is	- Local infiltration: At end of surgery to	BUPIVACAINE:
	blocking sodium	determined by lipid solubility	produce long-lasting post-surgical	- Onset of action is slower than lidocaine and anesthesia is long acting - 2-
	channels to	- $\uparrow$ lipid solubility $\rightarrow$ $\uparrow$ potency	analgesia (reduces need for narcotics)	4 hours, extended with epinephrine for up to 7 hours.
	prevent	- Increase plasma protein binding	- I/V infusion: For control of cardiac	- More cardio-toxic than lidocaine, difficult to treat.
	depolarizatio	of a drug $\rightarrow$ prolong it action $\rightarrow \uparrow$	arrhythmias (e.g., lidocaine for ventricular	- Metabolized in the liver and excreted by the kidneys
		potency	arrhythmias)	- Contraindication: known hypersensitivity
Lo		Addition of vasoconstrictor:		ROPIVACAINE:
cal		Prolongation of anesthetic action,		- Less toxic, long-lasting LA.
an		decreased risk of toxicity and		- Undergoes extensive hepatic metabolism, with only 1% of the drug
est		decrease in bleeding from surgical		eliminated unchanged in the urine.
he		manipulation.		- Ropivacaine is slightly less potent than bupivacaine.
tic		Choice of local anesthetics:		Local Anesthetic Toxicity:
S		- Onset & Duration		- CNS: Initially circumoral numbness, dizziness, tinnitus, visual change.
		- Sensory vs. motor block		Later drowsiness, disorientation, slurred speech, loss of consciousness,
		- Potential for toxicity		convulsions & finally respiratory depression
				- Cardiovascular System: Myocardial depression and vasodilation
				hypotension and circulatory collapse
				- Allergic reactions: rare (less than 1%) rash, bronchospasm
				Prevention and Treatment of Toxicity:
				- All Cases: Assure adequate ventilation & administer supplemental O <sub>2</sub> .
				- Seizures: Midazolam
				- Hypotension: Trendelenburg position (head down , legs up),
				- IV fluid bolus (Isotonic Saline or LR),
				- Vasopressor (Dopamine if refractory to above).
				- Dysrhythmias: As per ACLS protocol (but do not administer further
				Lidocaine)